Atherosclerotic Cardiovascular DiseaseNCT04462159
The Young Heart Study
A study testing Risk Reduction Program in people with Atherosclerotic Cardiovascular Disease and Coronary Artery Disease, run by Northwell Health at 1 site in United States.
Trial summary
The purpose of our project is to better understand the characteristics of the young patients with coronary artery disease presenting for cardiac catheterization at our institution and to put forth a program to optimize their risk factors with a focus on gender differences. Read more about this study
- Who is it for?
- Ages 18 to 59 years
- Conditions the study is for
- Atherosclerotic Cardiovascular Disease, Coronary Artery Disease
- What is being tested?
- Risk Reduction Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 27 May 2020to 27 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 59 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patient with atherosclerotic cardiovascular disease
Who cannot join
- Age 60 years or older
- Physical limitation that will prevent them from being part of the exercise part of the study
- Given that all the sessions will be given in English, participants not fluent in English will be excluded
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Young Patients With Coronary Heart Disease Trial- Assessment of Risk Factors and the Impact of a Risk Reduction Program
The purpose of our project is to better understand the characteristics of the young patients with coronary artery disease presenting for cardiac catheterization at our institution and to put forth a program to optimize their risk factors with a focus on gender differences. We will assess traditional and non-traditional risk factors, as well as genetics and environment. These characteristics will be compared by gender to determine unique factors related to women that could subsequently be targeted. The program will begin with universal education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component. These sessions will be done virtually in order to comply with social distancing until in person sessions can resume.
The investigational endpoints of this program will include a variety of cardiovascular disease (CVD) risk factors, biomarkers, lifestyle behaviors, quality of life and guideline-based medical regimen. At the end of this phase, we aim to both better understand differences in risk factors and the interventions with the biggest impact in terms of risk factor optimization in men vs. women.
Read the detailed description
After enrollment, participants will meet with researchers where baseline character-istics will be obtained including biometrics such as weight, height, blood pressure, abdominal circumference, etc., as well as a questionnaire that will include validat-ed screening tools for the screening for depression, anxiety, and stress, which are considered non-traditional risk factors for heart disease. The questionnaire will also include other aspects of the participant's lifestyle that could help better understand their risk for heart disease. This questionnaire will be available to be filled out on paper, via email which will be linked with REDCap, and in a tablet provided by our team with the data also being uploaded directly to REDCap.
Blood will also be collected by venipuncture (approximately 12milliliters, 6-8mL for standard of care labs, and 3-4mL for research labs) to assess inflammatory markers, lipids and glucose levels. If based on this initial screening, participants are thought to be at high risk for genetic disease, which likely predisposed them to develop heart disease, they will be offered genetic testing as part of their routine clinical care outside of this research, and an additional consent form will then be provided. We are planning to only recommend genetic testing as per clinical care in those for whom it is recommended by clinical guidelines. When a patient is deemed eligible from a clinical standpoint, they will be referred to our cardio ge-nomics team and be consented as per their clinical protocols and samples, either saliva or blood acquired by venipuncture (about 5ml), will be obtained. Source of sample will be determined by cardio genomics team and this will also fall under their standard of care. If the patient is being enrolled in the outpatient setting and has lab work within the past month, assuming no changes have been made to lipid lowering therapies during that time, we will only need to draw 3-4mL for research labs and possibly one additional tube for Lipoprotein A, as it is not commonly in-cluded in basic lab work.
During their initial consultation while in the hospital, their individual risk would be assessed and the patient will receive counseling on how to further improve said risk. These goals will be reinforced and measures to ensure those goals are met will be implemented when the patient comes to clinic within 2 weeks from their cardiac catheterization. During that visit, they will also be educated on the process of heart disease. Frequency of follow up in clinic will be determined on an individual basis based on individual risk factors, however, all patients are expected to be seen for a minimum of 3 times during those 6 months.
Soon after seeing us for that initial visit in clinic, the group risk reduction program will begin and will last for 6 months with 2 sessions per month (every other week), out of which participants will be required to attend at least 6 for maximum benefit. The sessions will include an exercise and nutrition program.
The nutrition program will be given by a Registered Dietitian Nutritionist and it will consist of a 60min session that will include about 10-15min education, 30min for a cooking demonstration where participants will be able to participate in the process of making heart healthy foods, and 10-15min for questions and answers. Food al-lergies will be reviewed prior to initiation of each session.
The exercise portion of the program will be led by a RRCA Level 1 Certified Coach from Achilles International and the exercise will be low level exercise, at a level lower than even cardiac rehabilitation, which is usually recommended for patients after cardiac procedures. Regardless, the patient's cardiologist will indicate in writ-ing that it is safe to proceed with these sessions, which will be a 60min session provided by an exercise specialist.
Both nutrition and exercise sessions will occur between 5:30-6:30pm or 6pm-7pm at the Friedman Institute for Diabetes, and if the weather allows, some of the exer-cise sessions will be at Central Park. If needed, participants can also see a psy-chologist. Once the risk reduction program has ended, within a month we will re-evaluate the participants, repeat the initial questionnaire (excluding the demo-graphic data, past medical history and family history sections) and repeat blood work, with the exception of referral for genetic testing.
The registered dietitian and exercise coach are not considered investigators on this study as they will be performing their routine job function and will not be giving any new or different information to the participants of this study than what they would give to any other person joining them who are not part of this study. Addi-tionally, they will not be collecting any data either.
Results will be analyzed by gender with the intention to assess if some characteris-tics are unique to women compared to men, and the impact of the program on risk factors will also be assessed. Participants will also be called by one of the re-searchers about 1 month after the program has finished to assess if any changes in their lifestyle have persisted after the program, and once a year to follow up on cardiovascular events for 5yrs.
Addendum:
The Young Heart Study was designed to help subjects identify, educate, and reduce their risk of cardiovascular disease. The original structure of the study was to hold in-person sessions geared towards mental health, nutrition, and exercise. The widespread impact of COVID-19 forced the research team to pivot from the previ-ous model and include innovative virtual supplemental content.
The Young Heart Study has developed 3 instructional videos in the areas of mental health, nutrition, and exercise. These videos will be used in addition to physically distanced in-person events in accordance with CDC recommendations. The virtual content will not replace the original in-person events and is to be used in addition to the original study procedures.
The revised protocol is for ALL subjects to watch the video content and answer a short experiential survey (included on separate document). This survey will help the research team gauge impact of the videos and determine use case for the remain-der of the study.
The post-study survey provided after the 6 month period will be used to gauge perceived improvement by participant, improve relevant data collection, and add additional qualitative information to study team.
- Being tested
- Risk Reduction Program
- Keywords
- cardiovascular disease, coronary artery disease, myocardial infarction, risk factors, gender disparities, novel biomarkers, lifestyle behaviors
- Medical subject headings
- Atherosclerosis, Coronary Artery Disease, Cardiovascular Diseases, Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Risk Reduction ProgramBehavioural
Education, exercise, teaching kitchen and nutrition, and psychological support
| Study group | Role | What they receive |
|---|---|---|
| Risk Reduction Program | Experimental | All participants will receive education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component. Receives: Behavioral: Risk Reduction Program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Cardiovascular (CV) Risk Factor - Cholesterol levels
Will assess changes pre and post intervention in Low Density Lipoprotein Cholesterol level (measured in mg/dL)
Measured: 6 months
Change in CV Risk Factor - Blood pressure
Will assess changes pre and post intervention in blood pressure (mmHg)
Measured: 6 months
Change in CV Risk Factor - Glucometabolic state (A1C)
Will assess changes pre and post intervention in glycemic control measured by the hemoglobin A1C (%)
Measured: 6 months
Change in CV Risk Factor - Smoking Status
Will assess changes pre and post intervention in smoking status (including quantity of cigarettes)
Measured: 6 months
Change in CV Risk Factor - Physical activity/inactivity
Will assess changes pre and post intervention in physical activity which will be done through a questionnaire where participants will report the frequency and intensity of exercise
Measured: 6 months
Change in CV Risk Factor - Overweight/Obesity
Will assess changes in weight by weighing patients on initial visit and again at follow-up. This value will be used in combination with patient's height to evaluate changes in body mass index.
Measured: 6 months
Change in CV Risk Factors - Diet
Will assess changes pre and post intervention in diet which will be done via a food intake questionnaire
Measured: 6 months
Change in CV Risk Factors - TMAO levels
Will assess changes pre and post intervention in trimethylamine N-oxide (TMAO) levels (microM)
Measured: 6 months
Change in CV Risk Factors - hs-CRP levels
Will assess changes pre and post intervention in high sensitive C-reactive protein (hs-CRP) measured in mg/L
Measured: 6 months
Change in Quality of Life Score
Surveys of Quality of Life and emotional well-being will be given at baseline and again at the end of the program
Measured: 6 months
Secondary outcomes (1)
Number of Cardiovascular events
Cardiovascular events assessed by a yearly phone call to the patient for up to 5 yrs
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2020
- Study start27 May 2020
- Primary completion28 Mar 2022
- Study completion27 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atherosclerotic Cardiovascular DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Northwell Health
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Eugenia Gianos, MD, Principal investigator, Northwell Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04462159
- Sponsor's protocol ID
- 20-0073
- Status last verified
- Oct 2023
- First submitted
- 20 Feb 2020
- Last updated
- 1 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Young Patients With Coronary Heart Disease Trial- Assessment of Risk Factors and the Impact of a Risk Reduction Program
- ClinicalTrials.gov ID
- NCT04462159
- Acronym / sponsor ID
- 20-0073
- Keywords
- cardiovascular disease, coronary artery disease, myocardial infarction, risk factors, gender disparities, novel biomarkers, lifestyle behaviors
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Northwell HealthUniversity, hospital or other
- Study start
- 27 May 2020 (actual)
- Primary completion
- 28 Mar 2022 (actual)
- Study completion
- 27 May 2026 (estimated)
- First posted
- 8 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of our project is to better understand the characteristics of the young patients with coronary artery disease presenting for cardiac catheterization at our institution and to put forth a program to optimize their risk factors with a focus on gender differences. We will assess traditional and non-traditional risk factors, as well as genetics and environment. These characteristics will be compared by gender to determine unique factors related to women that could subsequently be targeted. The program will begin with universal education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component. These sessions will be done virtually in order to comply with social distancing until in person sessions can resume.
The investigational endpoints of this program will include a variety of cardiovascular disease (CVD) risk factors, biomarkers, lifestyle behaviors, quality of life and guideline-based medical regimen. At the end of this phase, we aim to both better understand differences in risk factors and the interventions with the biggest impact in terms of risk factor optimization in men vs. women.
Detailed description
After enrollment, participants will meet with researchers where baseline character-istics will be obtained including biometrics such as weight, height, blood pressure, abdominal circumference, etc., as well as a questionnaire that will include validat-ed screening tools for the screening for depression, anxiety, and stress, which are considered non-traditional risk factors for heart disease. The questionnaire will also include other aspects of the participant's lifestyle that could help better understand their risk for heart disease. This questionnaire will be available to be filled out on paper, via email which will be linked with REDCap, and in a tablet provided by our team with the data also being uploaded directly to REDCap.
Blood will also be collected by venipuncture (approximately 12milliliters, 6-8mL for standard of care labs, and 3-4mL for research labs) to assess inflammatory markers, lipids and glucose levels. If based on this initial screening, participants are thought to be at high risk for genetic disease, which likely predisposed them to develop heart disease, they will be offered genetic testing as part of their routine clinical care outside of this research, and an additional consent form will then be provided. We are planning to only recommend genetic testing as per clinical care in those for whom it is recommended by clinical guidelines. When a patient is deemed eligible from a clinical standpoint, they will be referred to our cardio ge-nomics team and be consented as per their clinical protocols and samples, either saliva or blood acquired by venipuncture (about 5ml), will be obtained. Source of sample will be determined by cardio genomics team and this will also fall under their standard of care. If the patient is being enrolled in the outpatient setting and has lab work within the past month, assuming no changes have been made to lipid lowering therapies during that time, we will only need to draw 3-4mL for research labs and possibly one additional tube for Lipoprotein A, as it is not commonly in-cluded in basic lab work.
During their initial consultation while in the hospital, their individual risk would be assessed and the patient will receive counseling on how to further improve said risk. These goals will be reinforced and measures to ensure those goals are met will be implemented when the patient comes to clinic within 2 weeks from their cardiac catheterization. During that visit, they will also be educated on the process of heart disease. Frequency of follow up in clinic will be determined on an individual basis based on individual risk factors, however, all patients are expected to be seen for a minimum of 3 times during those 6 months.
Soon after seeing us for that initial visit in clinic, the group risk reduction program will begin and will last for 6 months with 2 sessions per month (every other week), out of which participants will be required to attend at least 6 for maximum benefit. The sessions will include an exercise and nutrition program.
The nutrition program will be given by a Registered Dietitian Nutritionist and it will consist of a 60min session that will include about 10-15min education, 30min for a cooking demonstration where participants will be able to participate in the process of making heart healthy foods, and 10-15min for questions and answers. Food al-lergies will be reviewed prior to initiation of each session.
The exercise portion of the program will be led by a RRCA Level 1 Certified Coach from Achilles International and the exercise will be low level exercise, at a level lower than even cardiac rehabilitation, which is usually recommended for patients after cardiac procedures. Regardless, the patient's cardiologist will indicate in writ-ing that it is safe to proceed with these sessions, which will be a 60min session provided by an exercise specialist.
Both nutrition and exercise sessions will occur between 5:30-6:30pm or 6pm-7pm at the Friedman Institute for Diabetes, and if the weather allows, some of the exer-cise sessions will be at Central Park. If needed, participants can also see a psy-chologist. Once the risk reduction program has ended, within a month we will re-evaluate the participants, repeat the initial questionnaire (excluding the demo-graphic data, past medical history and family history sections) and repeat blood work, with the exception of referral for genetic testing.
The registered dietitian and exercise coach are not considered investigators on this study as they will be performing their routine job function and will not be giving any new or different information to the participants of this study than what they would give to any other person joining them who are not part of this study. Addi-tionally, they will not be collecting any data either.
Results will be analyzed by gender with the intention to assess if some characteris-tics are unique to women compared to men, and the impact of the program on risk factors will also be assessed. Participants will also be called by one of the re-searchers about 1 month after the program has finished to assess if any changes in their lifestyle have persisted after the program, and once a year to follow up on cardiovascular events for 5yrs.
Addendum:
The Young Heart Study was designed to help subjects identify, educate, and reduce their risk of cardiovascular disease. The original structure of the study was to hold in-person sessions geared towards mental health, nutrition, and exercise. The widespread impact of COVID-19 forced the research team to pivot from the previ-ous model and include innovative virtual supplemental content.
The Young Heart Study has developed 3 instructional videos in the areas of mental health, nutrition, and exercise. These videos will be used in addition to physically distanced in-person events in accordance with CDC recommendations. The virtual content will not replace the original in-person events and is to be used in addition to the original study procedures.
The revised protocol is for ALL subjects to watch the video content and answer a short experiential survey (included on separate document). This survey will help the research team gauge impact of the videos and determine use case for the remain-der of the study.
The post-study survey provided after the 6 month period will be used to gauge perceived improvement by participant, improve relevant data collection, and add additional qualitative information to study team.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Risk Reduction Program | Experimental | Behavioral: Risk Reduction ProgramAll participants will receive education about the process of atherosclerosis, risk factors contributing to the disease and specific risk factor goals for each patient for the 6 month program. The patients will then be part of a bimonthly 6 month cardiovascular risk reduction program that will offer both a nutritional program with teaching kitchen component, and exercise instruction lead by an exercise physiologist. Psychological support will be provided to address stress that impairs quality of life, depression or anxiety to fully optimize the lifestyle component. |
Who may qualify
- Ages
- 18 to 59 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Patient with atherosclerotic cardiovascular disease
Key exclusion criteria (3 listed)
- Age 60 years or older
- Physical limitation that will prevent them from being part of the exercise part of the study
- Given that all the sessions will be given in English, participants not fluent in English will be excluded
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Risk Reduction ProgramEducation, exercise, teaching kitchen and nutrition, and psychological support | Behavioural | Risk Reduction Program |
Primary outcome
Change in Cardiovascular (CV) Risk Factor - Cholesterol levels
Time frame: 6 months
Will assess changes pre and post intervention in Low Density Lipoprotein Cholesterol level (measured in mg/dL)
Change in CV Risk Factor - Blood pressure
Time frame: 6 months
Will assess changes pre and post intervention in blood pressure (mmHg)
Change in CV Risk Factor - Glucometabolic state (A1C)
Time frame: 6 months
Will assess changes pre and post intervention in glycemic control measured by the hemoglobin A1C (%)
Change in CV Risk Factor - Smoking Status
Time frame: 6 months
Will assess changes pre and post intervention in smoking status (including quantity of cigarettes)
Change in CV Risk Factor - Physical activity/inactivity
Time frame: 6 months
Will assess changes pre and post intervention in physical activity which will be done through a questionnaire where participants will report the frequency and intensity of exercise
Change in CV Risk Factor - Overweight/Obesity
Time frame: 6 months
Will assess changes in weight by weighing patients on initial visit and again at follow-up. This value will be used in combination with patient's height to evaluate changes in body mass index.
Change in CV Risk Factors - Diet
Time frame: 6 months
Will assess changes pre and post intervention in diet which will be done via a food intake questionnaire
Change in CV Risk Factors - TMAO levels
Time frame: 6 months
Will assess changes pre and post intervention in trimethylamine N-oxide (TMAO) levels (microM)
Change in CV Risk Factors - hs-CRP levels
Time frame: 6 months
Will assess changes pre and post intervention in high sensitive C-reactive protein (hs-CRP) measured in mg/L
Change in Quality of Life Score
Time frame: 6 months
Surveys of Quality of Life and emotional well-being will be given at baseline and again at the end of the program
1 secondary outcome
Number of Cardiovascular events
Time frame: 5 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Nov 2023.
- Individual participant dataSharing planned: No
Related trials for Atherosclerotic Cardiovascular Disease
Recruiting
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
Coronary Arterial Disease (CAD), Plaque
Recruiting
Personalised Multicomponent Exercise Programme in Peripheral Arterial Disease
Peripheral Arterial Disease, Intermittent Claudication
Recruiting
Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Atherosclerosis Cardiovascular Disease
Active, not recruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Atherosclerotic Cardiovascular Disease, Overweight
Active, not recruitingObservational study
A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Spain)
Atherosclerotic Cardiovascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eugenia Gianos, MD principal investigator
Northwell Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Risk Reduction Program in people with Atherosclerotic Cardiovascular Disease and Coronary Artery Disease, run by Northwell Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Cardiovascular (CV) Risk Factor - Cholesterol levels (time frame: 6 months). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2023.